(See SLDB stock forecast) Next, we have Foghorn Therapeutics ... development of FHD-909 is proceeding in partnership with Eli Lilly. FHD-909 is an oral, first-in-class, highly potent, and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

HC Wainwright reaffirmed their buy rating on shares of Foghorn Therapeutics (NASDAQ:FHTX – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $ ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Foghorn Therapeutics has a 1 year low of $3.86 and a 1 year high of $10.25. The firm has a 50 day moving average of $4.75 and a 200-day moving average of $6.78. Get Foghorn Therapeutics alerts: ...

First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated ...

Like many pharma stocks, Eli Lilly (NYSE ... Of course, by that time, Lilly and Novo Nordisk may see competitors emerge. For example, Viking Therapeutics is studying its dual GIP/GLP-1 receptor ...

Eli Lilly stock has advanced ... Of course, by that time, Lilly and Novo Nordisk may see competitors emerge. For example, Viking Therapeutics is studying its dual GIP/GLP-1 receptor agonist ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.57 per share a year ago.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...